# Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects

> **NCT02882425** · PHASE1 · COMPLETED · sponsor: **Actelion** · enrollment: 19 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Selexipag for intravenous use
- **DRUG:** Selexipag for oral use

## Key facts

- **NCT ID:** NCT02882425
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02882425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02882425, "Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02882425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*